Mirae Asset Global Investments Co., Ltd. Bridge Bio Pharma, Inc. Transaction History

Mirae Asset Global Investments Co., Ltd.

$20 Billion
Q2 2024

A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 5,587 shares of BBIO stock, worth $149,340. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,587

Previous 61,744 90.95%

Holding current value

$149,340

Previous $1.91 Million 92.61%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 30, 2024	SELL	$23.0 - $31.04 $1.29 Million - $1.74 Million	-56,157 Reduced 90.95%	5,587 $141,000
Q1 2024 May 01, 2024	SELL	$27.35 - $40.45 $110,193 - $162,973	-4,029 Reduced 6.13%	61,744 $1.91 Million
Q4 2023 Jan 24, 2024	BUY	$24.02 - $43.89 $21,714 - $39,676	904 Added 1.39%	65,773 $2.66 Million
Q3 2023 Oct 26, 2023	SELL	$16.89 - $35.01 $58,794 - $121,869	-3,481 Reduced 5.09%	64,869 $1.71 Million
Q2 2023 Aug 10, 2023	BUY	$13.29 - $18.01 $99,648 - $135,038	7,498 Added 12.32%	68,350 $1.18 Million
Q1 2023 May 04, 2023	BUY	$7.17 - $18.55 $96,264 - $249,052	13,426 Added 28.31%	60,852 $1.01 Million
Q4 2022 Feb 09, 2023	BUY	$6.74 - $11.52 $559 - $956	83 Added 0.18%	47,426 $361,000
Q3 2022 Nov 10, 2022	BUY	$7.94 - $12.36 $106,102 - $165,166	13,363 Added 39.33%	47,343 $471,000
Q2 2022 Jul 26, 2022	BUY	$5.21 - $12.14 $177,035 - $412,517	33,980 New	33,980 $308,000
Q4 2021 Feb 08, 2022	SELL	$11.38 - $53.41 $69,247 - $324,999	-6,085 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$46.87 - $64.24 $285,203 - $390,900	6,085 New	6,085 $285,000

Others Institutions Holding BBIO

# of Institutions

292

Shares Held

175M

Call Options Held

8.66M

Put Options Held

2.76M

View Full List

About BridgeBio Pharma, Inc.

Ticker BBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 148,246,000
Market Cap $3.96B
Description
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...

More about BBIO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.

Account

Mirae Asset Global Investments Co., Ltd. Bridge Bio Pharma, Inc. Transaction History